Quinolinic acid

Discontinued Product

0225 has been discontinued.

View all NMDA Receptors products.
说明: Endogenous NMDA agonist and transmitter candidate
化学名: Pyridine-2,3-dicarboxylic acid
说明书
引用文献 (1)
评论
文献 (5)

生物活性 for Quinolinic acid

Quinolinic acid is an endogenous NMDA agonist and transmitter candidate. May distinguish between NMDA receptor subtypes.

技术数据 for Quinolinic acid

分子量 167.12
公式 C7H5NO4
储存 Store at RT
CAS Number 89-00-9
PubChem ID 1066
InChI Key GJAWHXHKYYXBSV-UHFFFAOYSA-N
Smiles OC(=O)C1=C(N=CC=C1)C(O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

产品说明书 for Quinolinic acid

分析证书/产品说明书
选择另一批次:

参考文献 for Quinolinic acid

参考文献是支持产品生物活性的出版物。

Monaghan and Beaton (1991) Quinolinate differentiates between forebrain and cerebellar NMDA receptors. Eur.J.Pharmacol. 194 123 PMID: 1676371

Prada de Carvalho et al (1996) The endogenous agonist quinolinic acid and the non-endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem.Int. 28 445 PMID: 8740453

Stone and Burton (1988) NMDA receptors and ligands in the vertebrate CNS. Prog.Neurobiol. 30 333 PMID: 2830636

Stone and Perkins (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in the rat CNS. Eur.J.Pharmacol. 72 411 PMID: 6268428

按产品操作查看相关产品

查看全部 NMDA Receptor Agonists

关键词: Quinolinic acid, Quinolinic acid supplier, agonists, Transmitter, candidate, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, 0225, Tocris Bioscience

1 篇 Quinolinic acid 的引用文献

引用文献是使用了 Tocris 产品的出版物。 Quinolinic acid 的部分引用包括:

Tsutsui-Kimura et al (2015) Milnacipran remediates impulsive deficits in rats with lesions of the ventromedial prefrontal cortex. Nat Commun 18 PMID: 25522418


Quinolinic acid 的评论

目前没有该产品的评论。 Be the first to review Quinolinic acid and earn rewards!

Have you used Quinolinic acid?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.